Let’s start
a conversation.
©2024 VintaBio LLC. All rights reserved.
We’ve harnessed the brightest minds in the industry
Meet the team
Our team is made up of veteran industry innovators and
up-and-coming technology pioneers with unique insights
and know-how into cell and gene therapy development and
manufacturing. With a combined 120 years of experience,
we have a deep understanding of the unique requirements
you need to meet throughout the product life cycle.
120+
years of cell & gene
therapy experience
50+
clinical and commercial
cell & gene therapy
programs supported
3
cell & gene therapy products
brought to market
20+
Biologics License
Applications (BLA) filings
Leadership
Be part of
something more
Each day we work to make gene therapies more accessible
to every patient in need.
Investors
Corporate Profile
Join us in advancing the future
of gene therapy access.
Careers
Open Roles
We are always seeking new talent
to work and collaborate with.
Junwei Sun
Co-founder & Advisor
Junwei Sun, M.S. M.B.A., is a co-founder and Advisor at VintaBio. He is a 20-year industry veteran with firsthand experience bringing gene therapy treatments to market. Prior to VintaBio, Junwei co-founded Spark Therapeutics and Opus Therapeutics where he was instrumental in the co-development of adeno-associated viral (AAV) vectors, establishing the foundation for the first two FDA-approved gene therapies, Luxterna® and Zolgenzma®. He also helped advance the preclinical and clinical studies which led to the approval of Luxturna®, an FDA approved medication used to treat rare genetic disorders of the retina. Prior to these co-founding roles, he served as the Administrative Director of the Center for Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia (CHOP) and built the Center for Advanced Retinal and Ocular Therapeutics (CAROT) at University of Pennsylvania. Junwei earned his M.S. in Immunology at the University of Pennsylvania and a M.B.A at the University of Western Ontario.
David Radspinner
Chief Executive Officer
David Radspinner is the Chief Executive Officer at VintaBio. He is a seasoned life science industry executive with 22 years of commercial, regulatory compliance, and quality assurance leadership experience. Prior to VintaBio, David was President of Biotherapeutics for ILC Dover where he was responsible for driving growth of the biopharmaceutical manufacturing product portfolio, including single use solutions for upstream and downstream bioprocessing. He has held several executive leadership roles for high-performing companies like Cytiva, GE Healthcare, Thermo Fisher Scientific, and Aventis Pharmaceuticals driving commercial excellence across, product management, marketing, sales and customer success. David holds a PhD in Analytical Chemistry from the University of Arizona and a bachelor’s in chemistry from the University of Wisconsin.
Jennifer Kingsley
Chief Commercial Officer
Jennifer is the Chief Commercial Officer at VintaBio. She brings over 25 years of commercial experience driving long-term sustainable growth for life science companies focusing on complex bioprocessing and cell and gene therapy solutions. Prior to VintaBio, she held various leadership roles at Cytiva, SAFC, and Life Technologies (now Thermo Fisher Scientific), where she successfully led global commercial strategy development, business development, and organizational development initiatives. Jennifer earned a bachelor’s degrees in Biological Sciences and Anthropology from Southern Methodist University and started her career at the bench before pivoting to a commercial role.
Lucia Fernandez
Vice President, Technology and Manufacturing
Lucia is the Vice President of Technology and Manufacturing for VintaBio. She brings a decade of BioProcessing industry experience with significant focus on cell and gene therapy treatments. Most recently she was responsible for translating 6 viral vector programs from proof of concept through to the clinic as the Head of Viral Vector Technology Transfer at the Center for Breakthrough Medicines. Prior to that she served as a Senior Scientist for Merck where she led the process development and technology transfer activities in vaccines and biologics development and commercialization. She was also a key contributor to the BLA filing of two blockbuster therapies; Keytruda®, a cancer immunotherapy treatment, and Vaxneuvance®, a vaccine developed to help protect against invasive disease caused by bacteria. Lucia achieved her MS and PhD in Biochemical engineering from Villanova University.
Angela Hughes
Head of Quality Assurance
Angela is the Head of Quality Assurance at VintaBio. She is a leading expert with deep experience navigating the regulatory pathway for cell and gene therapy product development. Over the past 25 years she has held key roles managing quality operations and compliance for global pharmaceutical companies such as Novartis, Pfizer, Sanofi Pasteur, Daiichi Sankyo, Medimmune, and Celgene (now BMS). She was also actively involved in the commercialization of the first approved CAR-T therapy, Kymriah®, a medication for the treatment of B-cell acute lymphoblastic leukemia which uses the body’s own T cells to fight cancer. Angela achieved a BS in Biology from the University of Scranton.
Michael Paeltz
Director of Analytical Development
Michael is the Director of Analytical Development at VintaBio. He has over 14 years of experience in the cell and gene therapy field establishing quality control practices for contract laboratories. He has extensive experience utilizing Lenti-virus particles for 2nd generation CAR-T and CAR-NK Therapies and has supported multiple projects from pre-IND through to commercial launch and manufacturing. His work led to the commercialization efforts of Atara’s EBV CAR-T® as well as the automation of CAR-T Cell Therapies utilizing the Cellares Cell Shuttle. Michael earned his MD from the Ohio State University and began his work in cell therapy through the Ohio State Medical Center.
Let’s start